Rhabdomyolysis and diabetes: A mitochondrial connection

Endocrine Practice

Volumn 13, Issue 3, 2007, Pages 313-316

  Wubben, Deborah P ^a   Bruns, Cristin M ^b   Seeger, Susanne ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Dean Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOPSY; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PATHOLOGY; RHABDOMYOLYSIS; SKELETAL MUSCLE;

ADULT; BIOPSY; DIABETES MELLITUS, TYPE 1; HUMANS; MALE; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; RHABDOMYOLYSIS;

EID: 34447567541     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.3.313     Document Type: Conference Paper

References (16)

1. Odawara M, Sasaki K, Yamashita K. Prevalence and clinical characterization of Japanese diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA(Leu(UUR)) gene. J Clin Endocrinol Metab. 1995;80:1290-1294.
2. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med. 1994;330:962-968.
3. Fukui M, Nakano K, Obayashi H, et al. High prevalence of mitochondrial diabetes mellitus in Japanese patients with major risk factors. Metabolism. 1997;46:793-795.
4. Maassen JA, van Essen E, van den Ouweland JM, Lemkes HH. Molecular and clinical aspects of mitochondrial diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109:127-134.
5. Morovvati S, Nakagawa M, Sato Y, Hamada K, Higuchi I, Osame M. Phenotypes and mitochondrial DNA substitutions in families with A3243G mutation. Acta Neurol Scand. 2002;106:104-108.
6. Thambisetty M, Newman NJ, Glass JD, Frankel MR. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist. 2002;8:302-312.
7. Koga Y, Akita Y, Takane N, Sato Y, Kato H. Heterogeneous presentation in A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. Arch Dis Child. 2000;82:407-411.
8. Mariotti C, Savarese N, Suomalainen A, et al. Genotype to phenotype correlations in mitochondrial encephalomyopathies associated with the A3243G mutation of mitochondrial DNA. J Neurol. 1995;242:304-312.
9. Suzuki Y, Iizuka T, Kobayashi T, et al. Diabetes mellitus associated with the 3243 mitochondrial tRNA(Leu)(UUR) mutation: insulin secretion and sensitivity. Metabolism. 1997;46:1019-1023.
10. Maassen JA. Mitochondrial diabetes: pathophysiology, clinical presentation, and genetic analysis. Am J Med Genet. 2002;115:66-70.
11. Spellberg B, Carroll RM, Robinson E, Brass E. mtDNA disease in the primary care setting. Arch Intern Med. 2001;161:2497-2500.
12. Kwon JH, Kim JS. Rhabdomyolysis in a patient with MELAS syndrome. Eur Neurol. 2003;50:123-124.
13. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003;17:265-285.
14. Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care. 2003;26:2482-2483.
15. Gangopadhyay KK, Ryder RE. Nontraumatic rhabdomyolysis: an unusual complication of diabetic hyperosmolar nonketotic (HONK) state. J R Soc Med. 2006;99: 200.
16. Varughese GI, Scarpello JH. Non-traumatic rhabdomyolysis: the emerging role of CYP 3A4 in diabetes mellitus. J R Soc Med. 2006;99:385-386.